Last updated: March 13, 2026
What Is the Drug?
NDC 00597-0140 is the Eliquis (apixaban) 5 mg tablet. Approved by the FDA for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT), and pulmonary embolism (PE).
Market Size and Demand Drivers
The global anticoagulant market is growing steadily, driven by aging populations and rising incidences of atrial fibrillation, DVT, and PE.
Key Market Data (2022-2024)
| Indicator |
Value |
Source |
| Global anticoagulant market size |
$9.2 billion |
Grand View Research[1] |
| CAGR (2022-2026) |
8.5% |
MarketsandMarkets[2] |
| U.S. atrial fibrillation prevalence (2023) |
~6.1 million |
CDC[3] |
| Estimated annual prescriptions (U.S.) |
1.3 million |
IQVIA[4] |
Competitive Landscape
- Eliquis (apixaban): Market share ~25-30% in oral anticoagulants (2023).
- Other major agents: Pradaxa (dabigatran), Xarelto (rivaroxaban), and warfarin.
- Eliquis's safety profile and dosing convenience have bolstered its market position.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP) per 30-day supply (U.S. 2023): approximately $450–$550.
- Average out-of-pocket cost for patients: $10–$50, due to insurance and patient assistance programs.
Historical Pricing Trends
| Year |
Approximate Price (30-day supply) |
Notes |
| 2019 |
$450 |
Initial launch price stabilizes |
| 2021 |
$470 |
Slight increase due to inflation and production costs |
| 2023 |
$500 |
Market competition influences pricing; insurance coverage remains stable |
Price Projections (2024-2028)
| Year |
Estimated Price Range (30-day supply) |
Assumptions |
| 2024 |
$510–$530 |
Patent exclusivity persists; minimal generic competition |
| 2025 |
$520–$540 |
Entry of generics in 2025 may reduce prices slightly |
| 2026 |
$490–$510 |
Increased generic market share lowers average price |
| 2027 |
$470–$490 |
Further generics and biosimilar options emerge |
| 2028 |
$450–$470 |
Market stabilizes at lower price points; cost-saving measures improve |
Impact of Patent and Generics
The patent for Eliquis expires around 2026. Entry of generics is projected to halve the price within 1-2 years post-expiry, as seen with other direct oral anticoagulants.
Regulatory and Policy Factors
- Pricing Regulations: U.S. Medicare and Medicaid negotiations could influence prices.
- Reimbursement Policies: Insurance coverage often affects actual cost for patients.
- Biosimilar/Aptamer Competition: Less likely in the near term due to the nature of anticoagulants but could influence the market over time.
Summary of Market Dynamics
- Market growth driven by increasing prevalence of target conditions.
- Pricing stability expected until patent expiration in 2026.
- Post-patent competition likely to significantly lower prices, increasing accessibility.
- Generic entry could see prices fall by approximately 50% within two years of patent expiry.
Key Takeaways
- NDC 00597-0140 (Eliquis) dominates the U.S. oral anticoagulant market, with a steady demand trajectory.
- Current prices range around $450–$550 per month, with minimal decrease expected until 2026.
- Post-expiry of patent protection, prices could decrease by 40–50% within 2 years due to generic competition.
- Market growth remains robust, but pricing pressures will intensify after patent expiration.
- Cost reductions will improve patient access, potentially expanding market size.
Frequently Asked Questions (FAQs)
-
When is Eliquis's patent expiration?
Patent protection is expected to expire in 2026, enabling generic competition.
-
How will generics affect the market size?
Generic entry will likely increase prescriptions due to lower costs, expanding overall market size.
-
What are the primary factors influencing Eliquis prices?
Patent status, generic competition, insurance reimbursement policies, and manufacturing costs.
-
How does Eliquis compare with other anticoagulants?
Eliquis has shown superior safety and efficacy profiles, maintaining a leading market share despite high pricing.
-
What regulatory changes could impact pricing?
Price negotiations under Medicare and Medicaid and potential drug pricing legislation could influence future pricing.
References
[1] Grand View Research. (2022). Anticoagulants Market Size, Share & Trends.
[2] MarketsandMarkets. (2023). Anticoagulants Market by Product, Application, and Region.
[3] CDC. (2023). Atrial Fibrillation Facts.
[4] IQVIA. (2023). U.S. Prescription Data for Oral Anticoagulants.
